Balyasny Asset Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-15,963
| Closed | -$783K | – | 3138 |
|
|
2025
Q4 | $783K | Sell |
15,963
-1,348,796
| -99% | -$62.9M | ﹤0.01% | 2301 |
|
|
2025
Q3 | $58.9M | Buy |
+1,364,759
| New | +$53.3M | 0.07% | 306 |
|
|
2024
Q4 | – | Sell |
-5,860
| Closed | -$240K | – | 2944 |
|
|
2024
Q3 | $240K | Sell |
5,860
-5,413
| -48% | -$221K | ﹤0.01% | 2519 |
|
|
2024
Q2 | $434K | Sell |
11,273
-361,849
| -97% | -$15.2M | ﹤0.01% | 2110 |
|
|
2024
Q1 | $16M | Buy |
373,122
+327,097
| +711% | +$13.5M | 0.03% | 728 |
|
|
2023
Q4 | $1.71M | Sell |
46,025
-1,065,879
| -96% | -$38.3M | ﹤0.01% | 1504 |
|
|
2023
Q3 | $40.3M | Buy |
+1,111,904
| New | +$39.5M | 0.08% | 332 |
|
|
2023
Q1 | – | Sell |
-2,064,244
| Closed | -$72.5M | – | 2857 |
|
|
2022
Q4 | $72.5M | Buy |
2,064,244
+1,288,198
| +166% | +$42.9M | 0.2% | 123 |
|
|
2022
Q3 | $22.8M | Buy |
776,046
+489,102
| +170% | +$18.5M | 0.07% | 389 |
|
|
2022
Q2 | $15.6M | Sell |
286,944
-617,344
| -68% | -$34.1M | 0.05% | 502 |
|
|
2022
Q1 | $49.2M | Buy |
904,288
+684,554
| +312% | +$37.2M | 0.16% | 151 |
|
|
2021
Q4 | $12.1M | Sell |
219,734
-189,430
| -46% | -$9.85M | 0.04% | 578 |
|
|
2021
Q3 | $19.5M | Buy |
+409,164
| New | +$20.6M | 0.08% | 347 |
|
|
2020
Q2 | – | Sell |
-87,428
| Closed | -$4.14M | – | 1273 |
|
|
2020
Q1 | $4.14M | Buy |
+87,428
| New | +$4.66M | 0.05% | 455 |
|
|
2018
Q1 | – | Sell |
-626,873
| Closed | -$29.2M | – | 2082 |
|
|
2017
Q4 | $27.8M | Buy |
626,873
+452,423
| +259% | +$20.9M | 0.09% | 311 |
|
|
2017
Q3 | $8.85M | Buy |
+174,450
| New | +$8.85M | 0.03% | 542 |
|
|
2017
Q2 | – | Sell |
-224,775
| Closed | -$11.8M | – | 1567 |
|
|
2017
Q1 | $11.8M | Buy |
224,775
+201,815
| +879% | +$10.2M | 0.06% | 436 |
|
|
2016
Q4 | $1.1M | Sell |
22,960
-70,489
| -75% | -$3.48M | 0.01% | 995 |
|
|
2016
Q3 | $5.04M | Sell |
93,449
-573,691
| -86% | -$31.5M | 0.03% | 499 |
|
|
2016
Q2 | $36.1M | Buy |
667,140
+412,296
| +162% | +$21.7M | 0.23% | 110 |
|
|
2016
Q1 | $12.9M | Buy |
+254,844
| New | +$12.7M | 0.08% | 332 |
|
|
2015
Q4 | – | Sell |
-107,615
| Closed | -$5.17M | – | 1311 |
|
|
2015
Q3 | $5.17M | Buy |
107,615
+99,638
| +1,249% | +$5.19M | 0.04% | 518 |
|
|
2015
Q2 | $415K | Buy |
+7,977
| New | +$449K | ﹤0.01% | 892 |
|
|
2014
Q4 | – | Sell |
-512,097
| Closed | -$29.4M | – | 726 |
|
|
2014
Q3 | $29.4M | Buy |
+512,097
| New | +$31.4M | 0.23% | 108 |
|
|
2014
Q2 | – | Sell |
-55,270
| Closed | -$3.69M | – | 685 |
|
|
2014
Q1 | $3.69M | Buy |
+55,270
| New | +$3.74M | 0.04% | 409 |
|
|
2013
Q3 | – | Sell |
-150,326
| Closed | -$9.39M | – | 621 |
|
|
2013
Q2 | $9.39M | Buy |
+150,326
| New | +$9.54M | 0.16% | 157 |
|
Other funds holding GSK
JEST
Balyasny Asset Management's GSK Position: Q1 2026 in Review
Balyasny Asset Management sold out of GSK (GSK) in Q1 2026, closing a stake of 15,963 shares — an estimated $783K sold.
Balyasny Asset Management first reported a position in GSK in Q2 2013 and held it in 26 quarters. The position peaked at $72.5M in Q4 2022. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Balyasny Asset Management reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
- Balyasny Asset Management sold 15,963 GSK shares in Q1 2026, an estimated $783K.
- Balyasny Asset Management first reported a position in GSK in Q2 2013 and held it in 26 quarters.
- Balyasny Asset Management's GSK position peaked at $72.5M in Q4 2022.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.